| SGLT2 Inhibitor |
0 |
1 |
| Type 2 Diabetes Mellitus |
0 |
0.99 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.78 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.7 |
| DPP-4 Inhibitors |
0 |
0.98 |
| Fractures |
0 |
0.97 |
| Geriatrics |
0 |
0.96 |
| Medicare |
0 |
0.13 |
| Medical Life |
0 |
0.12 |
| Bone |
0 |
0.11 |
| Bone Density |
0 |
0.11 |
| Match |
0 |
0.11 |
| Young Adult |
0 |
0.08 |
| Heart Failure (HF) |
0 |
0.07 |
| Renal Disease |
0 |
0.06 |
| Frailty |
0 |
0.05 |
| GLP-1 Receptor Agonist |
0 |
0.95 |
| Heart |
0 |
0.05 |
| Kidney |
0 |
0.05 |
| Kidney, Ureter, and Bladder |
0 |
0.05 |
| Type 1 Diabetes Mellitus |
0 |
0.05 |
| Diabetic Ketoacidosis |
0 |
0.03 |
| Dorsum |
0 |
0.03 |
| Endocrinology |
0 |
0.03 |
| Hip Fracture |
0 |
0.03 |
| Hospital |
0 |
0.03 |
| Hypoglycemia |
0 |
0.03 |
| Jobs |
0 |
0.03 |
| Maryland |
0 |
0.03 |
| Metabolism |
0 |
0.03 |
| Minerals |
0 |
0.03 |
| Nutrition |
0 |
0.03 |
| Pelvic Fracture |
0 |
0.03 |
| Pharmacoepidemiology |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Surgery |
0 |
0.03 |
| Syncope |
0 |
0.03 |